NasdaqCM - Nasdaq Real Time Price USD

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

7.10

-0.40

(-5.33%)

As of 3:15:04 PM EDT. Market Open.

We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 11 days ago

CRBP
-5.33%
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026 NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the

GlobeNewswire last month

CRBP
-5.33%
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

CRBP
-5.33%
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

Corbus Pharmaceuticals (CRBP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks last month

CRBP
-5.33%
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

CRBP
-5.33%
Corbus Pharmaceuticals: Q4 Earnings Snapshot

NORWOOD, Mass. AP) — Corbus Pharmaceuticals Holdings Inc. CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter.

Associated Press Finance last month

CRBP
-5.33%
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancerCRB 913 SAD/MAD obesity study expected to start in March 2025$149m of cash & investments as of December 31,2024 and cash runway expected through Q3 2027 NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a d

GlobeNewswire last month

CRBP
-5.33%
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the following upcoming investor conferences. B. Riley Securities Precision Oncology & Radiopharma Investor ConferenceFormat: Panel and one-on-one investor meetingsPanel Title: Unlocking the Full Potential of Nectin-4 Targeting TherapiesDate: February 28, 2025Time: 8:00 a.

GlobeNewswire 2 months ago

CRBP
-5.33%
Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate

On Friday, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced that data from its US and UK first-in-human dose escalation clinical study of CRB-701 (SYS6002) were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The Phase 1 Western dose escalation study enrolled participants with metastatic urothelial cancer (mUC) and other solid tumors associated with Nectin-4 expression. These included several tumor types not previously explored in China. A Dec

Benzinga 2 months ago

CRBP
-5.33%
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study Low levels of peripheral neuropathy and skin toxicity observed in both studies Clinical responses seen in urothelial (mUC) and cervical cancer participants in both studies First time targeting of head and neck squamous cell carcinoma (HNSCC) with CRB-701 yields multiple responses Dose optimization is underway with

GlobeNewswire 2 months ago

CRBP
-5.33%
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe (“Western study”) of CRB-701 (SYS6002) has been released. The corresponding up-to-date data will be presented as a poster during the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The data from 31 pa

GlobeNewswire 2 months ago

CRBP
-5.33%
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the Guggenheim SMID Cap Biotech Conference, to be held February 5-6, 2025 in New York, NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings. Guggenheim Securities SMID Cap Biotech ConferenceFormat: Fireside Cha

GlobeNewswire 2 months ago

CRBP
-5.33%
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced data from its first-in-human dose escalation clinical study conducted in the United States and the United Kingdom (“Western study”) of CRB-701 (SYS6002) will be presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), to be held in San Francisco, CA February 13–15, 2025. The poster is titled Phase 1 Dose-

GlobeNewswire 3 months ago

CRBP
-5.33%
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2025 in San Francisco, CA. Dr. Cohen will be presenting and attending investor meetings. 43rd Annual J.P. Morgan Healthcare ConferenceFormat: Presentation and one-on-one investor meetingsPre

GlobeNewswire 3 months ago

CRBP
-5.33%
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors (NCT06603844). CRB-601 is a

GlobeNewswire 4 months ago

CRBP
-5.33%
Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of Biotechnology The biotechnology sector is […]

Insider Monkey 4 months ago

CRBP
-5.33%
$FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer$

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, clea

GlobeNewswire 4 months ago

CRBP
-5.33%
Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now

We recently compiled a list of the 10 Oversold Healthcare Stocks To Invest In. In this article, we are going to take a look at where Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) stands against the other oversold healthcare stocks. The Promising Outlook for Healthcare Investments in 2024 Investing in healthcare stocks during lean economic times is generally […]

Insider Monkey 4 months ago

CRBP
-5.33%
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

NORWOOD, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 7th Annual Evercore HealthCONx Conference to be held December 3-5, 2024 in Coral Gables, FL. 7th Annual Evercore HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3, 2024Time:

GlobeNewswire 5 months ago

CRBP
-5.33%
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

NORWOOD, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference to be held November 19-21, 2024 in London, UK. Jefferies London Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 19, 2024Time: 10:30 a.m

GlobeNewswire 5 months ago

CRBP
-5.33%

Performance Overview

Return	CRBP	S&P 500 (^GSPC)
YTD	-39.83%	-5.39%
1-Year	-80.08%	+8.76%
3-Year	-30.19%	+34.67%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know

Corbus Pharmaceuticals: Q4 Earnings Snapshot

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now

Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Performance Overview